The valuation question that can derail a first investor meeting

Founders often think naming a precise valuation proves they are prepared. The evidence suggests the reverse: the strongest early conversations begin with a capital plan, then let price emerge from proof, investor demand and the structure of the round. A delayed valuation can be useful, but it is not free: founders and investors must still understand the ownership consequences.

Ben Botes, the writer behind Scale Signals, described a founder who spent four months taking 72 first meetings.

There was one concrete stake behind all that activity: not a single meeting became a deal.

Botes’s account, published in May 2026, did not portray a founder short of effort. The founder had access, conversations and apparent momentum. What was missing was sequence. Each first meeting had been treated as though it were already a negotiation over terms, before either side had established whether the investor understood the business, believed its stage or was right for the round.

That is where valuation causes trouble. A founder opens with a number, hoping it signals preparation. The investor hears a demand before hearing the case.

The question is not whether founders should know what their company might be worth. They should. The question is whether that should be the first thing they try to settle.

Usually, no.

A first meeting should begin somewhere less glamorous and far more useful: how much capital is needed, what it pays for, and what will be true when it has been spent. A working product? Early users? Revenue? A proof point that changes the next investor’s view of the business?

Only then does price acquire a job to do.

The number that feels like preparation

Most founders are taught a crude choice. Name a firm valuation and look decisive, or avoid the question and look unprepared.

Both instincts misunderstand valuation. It is not a preferred price tag. It is an estimate of a company’s value before new money arrives, shaped by stage, evidence, comparable transactions, use of capital and the appetite of investors who can actually fund that stage.

CRV, the US venture firm, describes valuation as an output rather than a target. Its useful test is practical: does the price provide enough capital to reach a milestone, keep dilution, meaning the ownership founders give away, reasonable, and bring in an investor who stays engaged?

The interesting part is that a founder can be perfectly serious about a number and still be using the wrong evidence. Public funding announcements make this worse. They are full of unusually successful companies and unusually flattering figures.

Seedtable’s 2026 analysis found that only 1.5% of funding rounds disclose a valuation. The disclosed deals were also much larger than typical ones: its reported Series A median post-money valuation was $400 million, compared with a typical round of $9 million.

That is not a market menu. It is a highlight reel.

For a closer look at why an impressive valuation can distract from the money that actually reaches a company, see The Most Dangerous Number in a Funding Announcement.

What investors hear when you say “$10 million”

Astera, which published a 2025 funding guide for health and science founders, warns that saying a number early can anchor expectations in ways the founder did not intend.

Consider its simple example. A founder says the company is worth $10 million. An investor who assumes the new round should buy about 20% of the company may infer a $50 million value after the investment. The founder may think they have stated a modest valuation. The investor may conclude that the founder’s expectations are detached from the evidence.

Nothing about the science, customers or team changed in that exchange. Only the order of the conversation did.

Astera’s funding guide highlights how one early valuation can trigger an investor’s very different assumptions. Photo: RDNE Stock project / Pexels, Pexels licence (free commercial use).

This is where most people stop looking. They call it a disagreement over valuation. It is often a disagreement over what needs to be proven next.

Imagine a health-science company with an early product. The investor does not merely need to know that the founder wants capital. They need to know which uncertainty the capital removes. Can the product be built? Will users return? Can early revenue become repeatable?

The capital plan gives those questions a shape. The valuation follows from how convincing the answers are.

GI Network's view: A founder who can explain what £1 of new capital turns into is negotiating from evidence. A founder who begins with valuation is asking the investor to supply the evidence for them.

America built a way to wait

In the United States, many early-stage companies do not settle a fixed price at the outset.

HSBC Innovation Banking’s 2026 guide to completed US financings says nearly one-third of rounds below $5 million use SAFEs. A SAFE, or Simple Agreement for Future Equity, takes investment now while delaying the final company price until a later financing.

HSBC Innovation Banking’s data shows that delaying a fixed price is common in smaller US funding rounds. Photo: Calvin Seng / Pexels, Pexels licence (free commercial use).

That matters because it overturns a common assumption. Delaying valuation is not automatically evasive. It can be a deliberate choice when the next milestone may substantially change the evidence available to both sides.

But a SAFE does not abolish valuation. It postpones it. And postponement has a price of its own.

Here is a worked illustrative example. Assume a founder needs $2 million to reach a meaningful milestone. If the company raises that $2 million now at a $10 million pre-money valuation, the new investor owns about 16.7% after the round. Existing holders retain about 83.3%.

Now assume instead that the founder takes $2 million through a SAFE with a $10 million post-money valuation cap, then later raises another $2 million in a priced round at a $13.2 million pre-money valuation. Ignoring discounts, option pools and other share changes, the SAFE investor begins with 20% and is diluted by the later round. Existing holders end with roughly 69.5%, the SAFE holder about 17.4%, and the new priced-round investor about 13.2%.

The comparison is deliberately simplified, but the decision is real. The SAFE route brought in more total capital, $4 million rather than $2 million, and gave the founder more time to prove the case. It also created more dilution. A founder therefore should not ask, “Can a SAFE avoid a difficult valuation conversation?” They should ask, “Do I need the extra time and evidence badly enough to accept the ownership cost of this structure?”

For investors, the same arithmetic asks a different question: does this instrument give us an ownership position that justifies the risk, and have we retained enough capital for later rounds?

Britain’s broad bands are a warning, not a menu

The UK offers a different version of the same lesson. Silicon Valley Bank’s 2023 VC Term Sheet Report found broad valuation ranges in UK venture transactions. Most seed valuations were below £9.9 million. For Series A transactions, 82% fell between £5 million and £34.9 million.

A term sheet is the document that sets out proposed investment terms. These figures show why there is no single market price for “a seed company”. Companies at the same named stage can have very different evidence, cash needs and investor demand.

Silicon Valley Bank’s UK term-sheet ranges reveal that stage labels do not produce one market price. Photo: Minh Nguyen / Wikimedia Commons, CC BY-SA 4.0.

At first glance, those wide bands look unhelpful. In fact, they identify the work that needs doing. Why does this company belong nearer one end than the other? What has it already proved? What will the proposed cash change?

That answer cannot rest on a headline valuation from an exceptional deal. It may rest on a working product, early customers, recurring revenue, efficient use of earlier capital, or a credible route to the next milestone. Yet even revenue needs inspection. As our analysis of bankable ARR explains, a reported number and a number an outside capital provider can rely on are not the same thing.

Put Astera’s warning, the US SAFE data and the UK valuation ranges side by side and a pattern appears that none of the reports quite states outright. The danger is not a high valuation or a low one. It is trying to sell a future-stage price using today’s evidence.

The investor’s quieter calculation

Founders often assume investors focus on valuation because they are trying to negotiate the number down. Sometimes they are. But experienced investors are also working through a portfolio problem.

First, they ask what ownership they need for an investment to matter. There is no universal answer, but the question must be explicit. An investor who needs a meaningful stake cannot treat a proposed price as an abstract compliment to the founder.

Second, they think about reserves, meaning money held back to invest in later rounds. If the company reaches its milestone and raises again, can the investor maintain enough ownership to justify its original conviction? The founder should ask this directly rather than assume that an investor’s enthusiasm today guarantees follow-on capital tomorrow. What Your VC Really Means by ‘We Have Reserves’ is a useful starting point.

Third comes adverse-selection risk. In plain English: why is this opportunity available on these terms? If investors who know the sector best repeatedly decline a round, a new investor should understand whether they have spotted something others missed, or whether they are simply receiving less flattering information later.

That is why a good investor asks about use of funds. They want to see whether the round resolves a defined uncertainty or merely extends the runway, the time before cash runs out. A company that raises too little at an attractive valuation may return to market without new proof. Then both founder and investor are negotiating from a weaker position.

The founder who understands this does not become defensive. They make the investor’s work easier: here is the milestone, here is its cost, here is the evidence it creates, and here is why this investor is a sensible partner for the next chapter.

Build the raise before you price it

For businesses, the practical task is not to avoid valuation. It is to make it the final answer to a stronger chain of reasoning.

Start with the current stage. Be honest about what exists today. Then name the one or two milestones that would materially change the company’s financing position. Calculate what it costs to reach them, with enough room to execute rather than merely announce progress.

Next, state what evidence will exist at the end. A tested product. Early users. Revenue. Some other result that changes what an investor can sensibly believe.

Only after that should you discuss price. If an investor asks early, do not dodge. Explain that the company is focused on matching the round to the capital plan and the right investor, then discuss a reasoned range or whether a SAFE suits the stage.

GI Network would test this plan from the investor’s side before a valuation range entered circulation: identify the proof gaps, calculate the capital needed to close them, examine the dilution under a priced round and a SAFE, map investors whose mandate matches the stage, and rehearse the ownership, reserve and follow-on questions their investment committees will ask.

The Milestone-First Test

Before naming a valuation, run four questions in order:

1. 1.Stage: What proof exists today: idea, product, early users, revenue or more?
2. 2.Spend: How much capital is genuinely required, and exactly what will it pay for?
3. 3.Shift: Which milestone will change what an investor can credibly believe about the business?
4. 4.Structure: Is there enough evidence to price the company now, or should a range or SAFE delay that decision, with its ownership cost clearly modelled?

If the first three answers are vague, the fourth is theatre.

The founder’s job is not to bring the loudest number into the first meeting. It is to show, step by step, what the money will turn the company into. Once both sides can see that destination, valuation stops being a demand and becomes the consequence of a case they can inspect.